These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 6301792

  • 1. Enalapril maleate (MK-421), a potent, nonsulfhydryl angiotensin-converting enzyme inhibitor: absorption, disposition, and metabolism in man.
    Ulm EH.
    Drug Metab Rev; 1983; 14(1):99-110. PubMed ID: 6301792
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Enalapril maleate and a lysine analogue (MK-521): disposition in man.
    Ulm EH, Hichens M, Gomez HJ, Till AE, Hand E, Vassil TC, Biollaz J, Brunner HR, Schelling JL.
    Br J Clin Pharmacol; 1982 Sep; 14(3):357-62. PubMed ID: 6289858
    [Abstract] [Full Text] [Related]

  • 4. Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.
    Gross DM, Sweet CS, Ulm EH, Backlund EP, Morris AA, Weitz D, Bohn DL, Wenger HC, Vassil TC, Stone CA.
    J Pharmacol Exp Ther; 1981 Mar; 216(3):552-7. PubMed ID: 6259322
    [Abstract] [Full Text] [Related]

  • 5. Enalapril, a nonsulfhydryl angiotensin-converting enzyme inhibitor.
    Vlasses PH, Larijani GE, Conner DP, Ferguson RK.
    Clin Pharm; 1985 Mar; 4(1):27-40. PubMed ID: 2982541
    [Abstract] [Full Text] [Related]

  • 6. Tissue angiotensin converting enzyme inhibition as an index of the disposition of enalapril (MK-421) and metabolite MK-422.
    Cohen ML, Kurz KD, Schenck KW.
    J Pharmacol Exp Ther; 1983 Jul; 226(1):192-6. PubMed ID: 6306224
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacological properties of the converting enzyme inhibitor, enalapril maleate (MK-421).
    Sweet CS.
    Fed Proc; 1983 Feb; 42(2):167-70. PubMed ID: 6295819
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Disposition of enalapril in the perfused rat intestine-liver preparation: absorption, metabolism and first-pass effect.
    Pang KS, Cherry WF, Ulm EH.
    J Pharmacol Exp Ther; 1985 Jun; 233(3):788-95. PubMed ID: 2989498
    [Abstract] [Full Text] [Related]

  • 11. Differential renal handling of angiotensin-converting enzyme inhibitors enalaprilat and lisinopril in rats.
    Lin JH, Chen IW, Ulm EH, Duggan DE.
    Drug Metab Dispos; 1988 Jun; 16(3):392-6. PubMed ID: 2900730
    [Abstract] [Full Text] [Related]

  • 12. Effect of dietary sodium on angiotensin-converting enzyme (ACE) inhibition and the acute hypotensive effect of enalapril (MK-421) in essential hypertension.
    Jackson B, Cubela R, Johnston CI.
    J Hypertens; 1984 Aug; 2(4):371-7. PubMed ID: 6099390
    [Abstract] [Full Text] [Related]

  • 13. New insights on effect of kidney insufficiency on disposition of angiotensin-converting enzyme inhibitors: case of enalapril and benazepril in dogs.
    Toutain PL, Lefebvre HP, Laroute V.
    J Pharmacol Exp Ther; 2000 Mar; 292(3):1094-103. PubMed ID: 10688628
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of captopril and enalapril on sodium excretion and blood pressure in sodium-deficient dogs.
    McCaa RE, Gillespie JB.
    Fed Proc; 1984 Apr; 43(5):1336-41. PubMed ID: 6323226
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antihypertensive activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor.
    Sweet CS, Gross DM, Arbegast PT, Gaul SL, Britt PM, Ludden CT, Weitz D, Stone CA.
    J Pharmacol Exp Ther; 1981 Mar; 216(3):558-66. PubMed ID: 6259323
    [No Abstract] [Full Text] [Related]

  • 19. Angiotensin converting enzyme activity in human serum: relationship to enzyme inhibitor in vivo and in vitro.
    Swanson BN, Hichens M, Mojaverian P, Ferguson RK, Vlasses PH, Dudash M.
    Res Commun Chem Pathol Pharmacol; 1981 Sep; 33(3):525-36. PubMed ID: 6276950
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.